CTRL Therapeutics is a biotechnology company focused on developing cell therapies for solid tumor treatments. The company utilizes cTRLs, a type of circulating T cell population found in the blood, to engineer therapies for cancer treatment.

cTRL Therapeutics

CTRL Therapeutics

We are building a new company to transform the cell therapy space by developing autologous cell therapies for patients with solid tumors. We are building a company culture based on collaboration, transparency, integrity, and commitment to excellence. We are looking for passionate people to be a part of this journey.

FACIT

General Catalyst

Intermountain Healthcare

At cTRL, we are aiming to unlock the next generation of solid tumor cancer therapies through cTRLs, a rare and potent circulating T cell population found in the blood and naturally equipped to fight #cancer.

This is enabled by our proprietary #IsoQore technology, which gently isolates cTRLs in large quantities with unprecedented speed and purity in a manner that is built to scale.

Learn more about our novel platform here: https://lnkd.in/e75_wUS7 

#Biotech #CellTherapy

A week ago, the members of the cTRL team came together in Chicago for a company offsite! From engaging cross-functional discussions to strategic planning sessions, we dove deep into our upcoming milestones, fueled by collaboration and innovation. But it wasn't all work and no play! We wrapped up the day on a high note with some friendly competition at the bowling alley, strengthening bonds and creating memories that will fuel our journey ahead. Here's to teamwork, strategy, and some fun!

 #TeamcTRL #Biotech

Get to know some of the talented individuals driving our success! Both team members bring unique skills and perspectives that contribute to our mission of unlocking the next generation of solid tumor #cancer therapies.

Shivu Sharma, Head of Strategy & Business Development, has over a decade of strategic leadership in oncology and cell therapy. He previously led product and portfolio strategy at Instil Bio and held key roles at Gilead Sciences and Kite Pharma, contributing to their strategic decisions and the Kite acquisition. Shivu also founded Big Pharma Sharma, a Substack publication offering industry insights. 

Vita Salsman, Head of Cell Therapy Manufacturing, has 19 years of experience in cell and gene therapy for solid tumors and has worked alongside scientific, regulatory, and clinical teams, bringing much needed new therapy options to critical patient populations, both adults and pediatrics. Leveraging her expertise in manufacturing operations, clinical trial logistics, and quality programs, her pivotal work has led to 8 completed phase I/II trials, treating a wide range of indications, including GBM, advanced sarcoma, and breast cancer.

#EmployeeSpotlight #Biotech #CellTherapy

We're #hiring a new Senior Scientist in Chicago, Illinois. Apply today or share this post with your network.

We're #hiring a new Senior Research Associate in Chicago, Illinois. Apply today or share this post with your network.

At cTRL, embracing diversity is one of our core values. As we celebrate #PrideMonth and #Juneteenth, we are reminded of the strength that comes from including and uplifting every unique voice in our community.

Pride Month honors the courage and resilience of the LGBTQ+ community, while Juneteenth commemorates the emancipation of enslaved African Americans and the ongoing pursuit of freedom and equality. Both observances highlight the importance of acceptance, inclusion, and the relentless pursuit of justice.

In the world of #cancer biotech, #diversity fuels our mission to develop groundbreaking treatments and solutions. By bringing together diverse perspectives, we foster creativity, drive progress, and enhance our ability to address the complex challenges of cancer.

Let's celebrate diversity as a strength and make it part of the biotech industry's DNA. Together, we can create a future where everyone thrives.

#Biotech #CellTherapy

COM:CTRL-TX

CTRL Therapeutics

locale

market

industry

website

linkedin

founding date

investor of

Metrics